Home
All Journals
Expert Opinion on Drug Safety
List of Issues
Volume 14, Issue 3

Expert Opinion on Drug Safety

Search in:

Advanced search Citation search

Citation search

Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site
Instructions for authors
Editorial policies
Editing services site

Journal metrics
Aims & scope
Journal information
Editorial board
News & calls for papers
Advertising information

Latest articles
Current issue
All volumes & issues
Special issues
Open access articles
Most read articles
Most cited articles

New content alerts
RSS

Subscription options & pricing

Buy a subscription

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Expert Opinion on Drug Safety, Volume 14, Issue 3 (2015)

Browse this journal

Latest articles
Current issue
List of issues
Special issues
Open access articles
Most read articles
Most cited articles

Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Drug Safety, Volume 14, Issue 3 (2015)

See all volumes and issues

Vol 23, 2024 Vol 22, 2023 Vol 21, 2022 Vol 20, 2021 Vol 19, 2020 Vol 18, 2019 Vol 17, 2018 Vol 16, 2017 Vol 15, 2016 Volume 14, 2015 Vol 13, 2014 Vol 12, 2013 Vol 11, 2012 Vol 10, 2011 Vol 9, 2010 Vol 8, 2009 Vol 7, 2008 Vol 6, 2007 Vol 5, 2006 Vol 4, 2005 Vol 3, 2004 Vol 2, 2003 Vol 1, 2002

Select to download all citations or PDFs

Download citations Download PDFs Download issue

Browse by section (All)

Display order (Default)
Published online date
Page number
Section A-Z
Most read
Most cited

Editorial

Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children

Malgorzata Pawlowska (Professor)

Pages: 343-348

Published online: 20 Jan 2015

AbstractforPegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children | Full Text | References | PDF (169.2 KB)

698 Views
5 CrossRef citations
0Altmetric

Free Access

Original Research

Article

Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilars

Gustavo Grampp PhD, Machaon Bonafede PhD MPH, Thomas Felix MD, Edward Li PharmD BCOP, Michael Malecki PhD & J Michael Sprafka PhD MPH

Pages: 349-360

Published online: 05 Jan 2015

AbstractforActive and passive surveillance of enoxaparin generics: a case study relevant to biosimilars | Full Text | References | PDF (347.3 KB) | Supplemental

682 Views
12 CrossRef citations
0Altmetric

Review

Drug-induced lupus

Robert L Rubin PhD

Pages: 361-378

Published online: 02 Jan 2015

AbstractforDrug-induced lupus | Full Text | References | PDF (455.8 KB)

1581 Views
68 CrossRef citations
0Altmetric

Systemic safety of anti-VEGF drugs: a commentary

Lauren J Scott (Medical Statistician) BSc MSc, Usha Chakravarthy (Professor of Ophthalmology and Vision Science) MBBS FRCS FRCOphth PhD, Barnaby C Reeves (Professorial Research Fellow in Health Services Research) BA DPhil MSc PhD MFPHM & Chris A Rogers (Reader in Medical Statistics) BSc PhD PGCE

Pages: 379-388

Published online: 09 Dec 2014

AbstractforSystemic safety of anti-VEGF drugs: a commentary | Full Text | References | PDF (407.3 KB)

866 Views
17 CrossRef citations
0Altmetric

Safety issues and concerns of new immunomodulators in rheumatology

Carlo Selmi MD PhD, Angela Ceribelli, Stanley M Naguwa, Luca Cantarini & Yehuda Shoenfeld

Pages: 389-399

Published online: 18 Dec 2014

AbstractforSafety issues and concerns of new immunomodulators in rheumatology | Full Text | References | PDF (270.8 KB)

1701 Views
32 CrossRef citations
0Altmetric

Efficacy and adverse effects of drugs used to treat adult cystic fibrosis

Ravi Chopra MD, Lisa Paul MD, Rajapriya Manickam MD, Wilbert S Aronow MD & George P Maguire MD

Pages: 401-411

Published online: 20 Jan 2015

AbstractforEfficacy and adverse effects of drugs used to treat adult cystic fibrosis | Full Text | References | PDF (253.5 KB)

635 Views
5 CrossRef citations
0Altmetric

Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence

Etienne Weisskopf, Céline J Fischer, Myriam Bickle Graz, Mathilde Morisod Harari, Jean-François Tolsa, Olivier Claris, Yvan Vial, Chin B Eap, Chantal Csajka (Professor of Clinical Pharmacy) & Alice Panchaud

Pages: 413-427

Published online: 02 Jan 2015

AbstractforRisk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence | Full Text | References | PDF (417.5 KB)

1783 Views
45 CrossRef citations
0Altmetric

Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Maeve McLaughlin (Rheumatology Clinical Research Fellow) MBBS (Lond) MA (Cantab) MRCP & Andrew Östör’s (Rheumatology Consultant, Associate Lecturer, Director of the Cambridge Rheumatology Research Unit) MA MB BS FRACP FRCP FRCP (Edin)

Pages: 429-437

Published online: 02 Jan 2015

AbstractforSafety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Full Text | References | PDF (211.8 KB)

659 Views
10 CrossRef citations
0Altmetric

Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?

Ezequiel Ridruejo MD

Pages: 439-451

Published online: 30 Dec 2014

AbstractforDoes hepatitis B virus therapy reduce the risk of hepatocellular carcinoma? | Full Text | References | PDF (278.4 KB)

272 Views
4 CrossRef citations
0Altmetric

Drug Safety Evaluation

Labetalol for hypertension in pregnancy

Laura A Magee (Clinical Professor of Medicine) MD FRCPC MSc FACP, Shirin Namouz-Haddad (Fellow, Clinical Pharmacology) MD, Vivien Cao (Bachelor of Science in Pharmacy (Candidate)) , Gideon Koren (Professor of Paediatrics) MD FRCPC & Peter von Dadelszen (Professor of Obstetrics and Gynaecology) MB ChB DPhil FRCSC

Pages: 453-461

Published online: 18 Feb 2015

AbstractforLabetalol for hypertension in pregnancy | Full Text | References | PDF (281.5 KB)

964 Views
17 CrossRef citations
0Altmetric

Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease

Chee H Loh (Fellow in Pulmonary and Critical Care Medicine) MD, James F Donohue (Professor of Medicine) MD & Jill A Ohar (Professor of Medicine) MD

Pages: 463-472

Published online: 07 Jan 2015

AbstractforReview of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease | Full Text | References | PDF (268.9 KB)

302 Views
7 CrossRef citations
0Altmetric

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C

Roberta D’Ambrosio MD, Alessio Aghemo MD & Massimo Colombo

Pages: 473-484

Published online: 03 Feb 2015

AbstractforAssessing safety and efficacy of sofosbuvir for the treatment of hepatitis C | Full Text | References | PDF (300.7 KB)

402 Views
8 CrossRef citations
0Altmetric

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients

Alana Dikopf PharmD BCOP, Kevin Wood MD & Ravi Salgia MD PhD

Pages: 485-493

Published online: 07 Feb 2015

AbstractforA safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients | Full Text | References | PDF (264.8 KB)

630 Views
13 CrossRef citations
0Altmetric

Explore articles

Latest
Open access
Most read
Most cited
Trending

Explore the most recently published articles

Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation

Kazumasa Yamamoto et al.

Review Article | Published online: 27 Apr 2024

A review on side effect management of second generation antipsychotics to treat schizophrenia: a drug safety perspective

Wolfgang Strube et al.

Review Article | Published online: 27 Apr 2024

Analysis of Inclisiran in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and Sex-specific Subgroups.

YuBin He et al.

Article | Published online: 27 Apr 2024

A Pharmacovigilance Study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration adverse event reporting system (FAERS) database

Tingxi Wu et al.

Article | Published online: 27 Apr 2024

View all latest articles

Download citations

Choose format

RIS (ProCit, Reference Manager)
BibTeX
RefWorks Direct Export

Download citations

Expert Opinion on Drug Safety (Vol.14, Iss.3, 2015)

Access Rights

Only articles that you have access rights to view will be downloaded. The green tick (full access) and orange padlock (open access) icons indicate that you have full access.

Do you want to proceed?